BLAINJECTIONINJECTABLE
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
6/8 — Strong
AVSOLA (infliximab-axxq) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2019.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVSOLA (infliximab-axxq) is a monoclonal antibody biosimilar that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is indicated for rheumatoid arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis), psoriasis, ankylosing spondylitis, and emerging uses in COVID-19 and chronic granulomatous disease. The drug works by binding TNF receptors and preventing inflammatory cascade activation, reducing disease progression and symptom burden.
$3MPart D
PeakProduct is in peak commercial phase with modest Part D uptake, indicating opportunity for market expansion and team growth in specialty channels.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Amgen is hiring 10 roles related to this product
Worked on AVSOLA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.